Articles On Oncosil Medical (ASX:OSL)

Bupa UK Insurance becomes the first health insurance company to provide reimbursement for OncoSil Medical’s (OSL) namesake device Following this milestone, OncoSil will be working with the London Clinic to provide reimbursement with other...

HitIQ and Volpara sign major deals in the US ECS Botanics makes first cannabis flower shipment to NZ Invex to commence Phase III study in Australia Following its extension contract with New Zealand Rugby a couple of weeks ago, HitIQ (ASX:...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Benchmark lifts on uranium, energy gains Small caps on energy and materials Newcomer Southern Palladium nails debut. Nails. It.   The benchmark is higher and the small cap index is a bit higher, but the real action on a lazy winter Wednes...

Highlights The benchmark ASX 200 was trading 0.59% up at 7,400.6 in the first 10 minutes of trading. A strong earnings report from Meta Platforms lifted the beaten down tech shares in the US on Thursday. The energy sector is the top p...

OncoSil Medical (OSL) signs its first commercial agreement in Spain for the OncoSil device with The Hospital Universitario de Fuenlabrada in Madrid The legally binding agreement worth €374,000 (A$553,000) will enable the hospital to treat...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

OncoSil Medical (OSL) places its shares in a trading halt pending the release of a capital raising announcement The medical technology company’s shares will remain in the halt until the earlier of April 29 or when the announcement is relea...

Halo Technologies (HAL) shares have plunged 27.5 per cent since its ASX debut yesterday. The listing came after the company raised more than $36 million through an IPO priced at $1.20 per share. The Australian business offers global s...

Local stocks hit cruise control heading into the Easter break, with steady gains across the ASX in a calm session. The microcap ASX Emerging Companies index rose by around 0.8%, slightly outperforming the big end of town. It followed a soli...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Okay, who poked the S&P/ASX Emerging Companies index (XEC) this morning? Someone woke the sleeping Spinosaurus – the largest carnivorous dinosaur on this planet – that lies at the heart of our beloved small cap thermometer. It started r...

Today is a good day for the OncoSil Medical Ltd (ASX: OSL) share price after the company released news of its pancreatic cancer treatment. The treatment – which comes in the form of a device – has surpassed a major milestone. It has been u...

OncoSil Medical (OSL) reports the company’s first commercial treatment of pancreatic cancer with the company’s flagship OncoSil device in Europe The treatment took place in Madrid, Spain at the Hospital Universitario de Fuenlabrada The dev...

Oncosil’s medical device is being used commercially for the first time in Europe NeuroScientific Biopharma is set to commence Phase 1 clinical trial after a successful toxicology study Medical device company, OncoSil Medical (ASX:OSL), su...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

OncoSil Medical (OSL) receives approval to undertake a fully funded clinical trial of its OncoSil device in Germany The trial will assess the performance of the OncoSil device in a comparison of the combination of standard-of-care (SoC) c...

Highlights OncoSil Medical has secured G-BA approval for a fully funded trial to evaluate its OncoSil device.   Successful results from the clinical trial are anticipated to lead to public insurance reimbursement funding of the devi...

Oncosil’s medical device will be used in a German government funded clinical trial PainChek to expand its technology in New Zealand Oncosil gets green light in Germany Medical device company OncoSil (ASX:OSL) announced that Germany has ap...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

The S&P/ASX200 pared earlier losses to finish ~0.2% lower. Wall Street lifted, but my word  — those gains were undermined by an after market bombshell from Facebook’s weird parent company, Meta ($FB), which slumped after totally disresp...

OncoSil Medical’s (OSL) device is approved for innovation funding for hospitals in Germany The German institute for the Hospital Remuneration System granted the OncoSil device with a “Positive Status 1” classification under the innovation...

The ASX 200 Health Index (XHJ) has fallen by 1.26% at the time of writing, compared to the broader index which is down by 0.12%. Medical device company OncoSil Medical (ASX:OSL) surged as high as 25% up today, after its device was granted a...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

The OncoSil Medical Ltd (ASX: OSL) share price is soaring higher on Friday after the company announced the publication of the PanCO clinical study’s final results. The study confirmed the company’s OncoSil device can be safely and successf...

OncoSil Medical (OSL) publishes the final results of the PanCO clinical study for its OncoSil device OncoSil is a targeted radioactive isotope implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound No radiation...

The ASX 200 Health Index (XHJ) is trading higher by 0.70% at the time of writing, compared to the broader index which is up by 0.55%. OncoSil Medical (ASX:OSL) has released the final results of the PanCO clinical study for the treatment of...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

As the world emerges from the pandemic, markets are now contending with an energy crisis, a global shipping glut and the prospect of central banks starting to raise interest rates. But so far this week, investors are shrugging it all off as...

OncoSil Medical (ASX:OSL) has announced the appointment of Professor Ricky Sharma to its board as a non-executive director.

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Summary The S&P/ASX200 ended lower by just 10 basis points at 7,394.30, shedding early gains. The index gained 0.3% to hit an all-time high of 7,417.60 during the day’s trade. Material sector emerged as the best performer, settlin...

The ASX clawed back initial gains to start the week, closing virtually flat today. The ASX 200 closed at 7,394 which was neck and neck with the point it closed at on Friday despite gaining as much as 0.3% in early trade. Meanwhile, the ASX...

Summary The ASX 200 has continued its momentum in the opening session, making a record high. All three major US stock indices also closed at an all-time high on Friday after a volatile week. Metals X Limited is planning to recommence...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

The Oncosil Medical Ltd (ASX: OSL) share price finished in positive territory during late-afternoon trade. This comes after the company announced it has received regulatory approval from an important strategic market. At market close, the...

On a day the ASX finished nearly 0.5 per cent up, tech stood alone in the red losing more than 2 per cent. The ASX 200 closed 0.56 per cent up at 7,068 points and the ASX Emerging Companies Index rose 0.41 per cent closing at 2,111 points....